资源类型

期刊论文 11

年份

2021 1

2020 1

2019 5

2018 1

2014 2

2013 1

关键词

生物标志物 2

CAR19 1

CART19 1

中医方证代谢组学 1

中药血清药物化学 1

代谢组学 1

嵌合抗原受体 1

工程化T细胞疗法 1

早期检测 1

有效性 1

液体活检 1

生物标记物 1

肝细胞癌 1

药物开发过程 1

证候 1

质量标记物 1

展开 ︾

检索范围：

排序： 展示方式：

Sepsis biomarkers: an omics perspective

null

《医学前沿（英文）》 2014年 第8卷 第1期   页码 58-67 doi: 10.1007/s11684-014-0318-2

摘要：

Sepsis is a common cause of death in hospitalized patients worldwide. The early detection of sepsis remains a great challenge for clinicians, and delayed diagnosis frequently undermines treatment efforts, thereby contributing to high mortality. Omics technologies allow high-throughput screening of sepsis biomarkers. This review describes currently available and novel sepsis biomarkers in the context of genomics, transcriptomics, proteomics, and metabolomics. The combination of these technologies can help refine the diagnosis of sepsis. This review paper serves as a reference for future studies that employ an integrated, multi-omics approach to disease identification.

关键词： sepsis     biomarker     genomics     transcriptomics     proteomics     metabolomics    

HTML PDF 收藏

Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets

null

《医学前沿（英文）》 2014年 第8卷 第4期   页码 404-418 doi: 10.1007/s11684-014-0379-2

摘要：

microRNAs (miRNAs) are a class of conserved, short, non-coding RNAs that have important and potent capacities to regulate gene expression at the posttranscriptional level. In the past several years, the aberrant expressions of miRNAs in the cardiovascular system have been widely reported, and the crucial roles of some special miRNAs in heart development and pathophysiology of various cardiovascular diseases have been gradually recognized. Recently, it was discovered that miRNAs are presented in peripheral circulation abundantly and stably. This has raised the possibility of using circulating miRNAs as biomarkers for diseases. Furthermore, some studies demonstrated that circulating miRNAs may serve as novel extracellular communicators of cell-cell communication. These discoveries not only reveal the functions of circulating miRNAs in cardiovascular system but also inform the development of miRNAs therapeutic strategies. In this review, we discuss the potential roles of circulating miRNAs in a variety of cardiovascular diseases from biomarkers to therapeutic targets to clearly understand the roles of circulating miRNAs in cardiovascular system.

关键词： microRNA     cardiovascular disease     biomarkers     therapeutic target    

HTML PDF 收藏

Progress on molecular biomarkers and classification of malignant gliomas

null

《医学前沿（英文）》 2013年 第7卷 第2期   页码 150-156 doi: 10.1007/s11684-013-0267-1

摘要：

Gliomas are the most common primary intracranial tumors in adults. Anaplastic gliomas (WHO grade III) and glioblastomas (WHO grade IV) represent the major groups of malignant gliomas in the brain. Several diagnostic, predictive, and prognostic biomarkers for malignant gliomas have been reported over the last few decades, and these markers have made great contributions to the accuracy of diagnosis, therapeutic decision making, and prognosis of patients. However, heterogeneity in patient outcomes may still be observed, which highlights the insufficiency of a classification system based purely on histopathology. Great efforts have been made to incorporate new information about the molecular landscape of gliomas into novel classifications that may potentially guide treatment. In this review, we summarize three distinctive biomarkers, three most commonly altered pathways, and three classifications based on microarray data in malignant gliomas.

关键词： malignant glioma     molecular biomarker     IDH1     MGMT     molecular classification    

HTML PDF 收藏

Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases

Zhen Xiang, Yingyan Yu

《医学前沿（英文）》 2019年 第13卷 第1期   页码 24-31 doi: 10.1007/s11684-019-0679-7

摘要： Immune checkpoint inhibitors are a promising strategy in the treatment of cancer, especially advanced types. However, not all patients are responsive to immune checkpoint inhibitors. The response rate depends on the immune microenvironment, tumor mutational burden (TMB), expression level of immune checkpoint proteins, and molecular subtypes of cancers. Along with the Cancer Genome Project, various open access databases, including The Cancer Genome Atlas and Gene Expression Omnibus, provide large volumes of data, which allow researchers to explore responsive or resistant biomarkers of immune checkpoint inhibitors. In this review, we introduced some methodologies on database selection, biomarker screening, current progress of immune checkpoint blockade in solid tumor treatment, possible mechanisms of drug resistance, strategies of overcoming resistance, and indications for immune checkpoint inhibitor therapy.

关键词： immune checkpoint blockade     sensitivity     resistance     data mining    

HTML PDF 收藏

Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular

Weiqi Rong, Yang Zhang, Lei Yang, Lin Feng, Baojun Wei, Fan Wu, Liming Wang, Yanning Gao, Shujun Cheng, Jianxiong Wu, Ting Xiao

《医学前沿（英文）》 2019年 第13卷 第2期   页码 250-258 doi: 10.1007/s11684-018-0632-1

摘要： Biomarkers for hepatocellular carcinoma (HCC) following curative resection are not currently sufficient for prognostic indication of overall survival (OS) and disease-free survival (DFS). The aim of this study was to investigate the prognostic performance of osteopontin (OPN), matrix metalloproteinase 7 (MMP7), and pregnancy specific glycoprotein 9 (PSG9) in patients with HCC. A total of 179 prospective patients with HCC provided plasma before hepatectomy. Plasma OPN, MMP7, and PSG9 levels were determined by enzyme-linked immunosorbent assay. Correlations between plasma levels, clinical parameters, and outcomes (OS and DFS) were overall analyzed. High OPN (≥149.97 ng/mL), MMP7 (≥2.28 ng/mL), and PSG9 (≥45.59 ng/mL) were prognostic indicators of reduced OS ( <0.001, <0.001, and =0.007, respectively). Plasma PSG9 protein level was an independent factor in predicting OS ( =0.008) and DFS ( =0.038). Plasma OPN+MMP7+PSG9 elevation in combination was a prognostic factor for OS ( <0.001). OPN was demonstrated to be a risk factor-associated OS in stage I patients with HCC and patients with low α-fetoprotein levels (<20 ng/mL). These findings suggested that OPN, MMP7, PSG9 and their combined panels may be useful for aiding in tumor recurrence and mortality risk prediction of patients with HCC, particularly in the early stage of HCC carcinogenesis.

关键词： biomarkers     OPN     MMP7     PSG9     HCC     prognosis    

HTML PDF 收藏

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

《医学前沿（英文）》 2019年 第13卷 第1期   页码 32-44 doi: 10.1007/s11684-018-0678-0

摘要：

Immunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint inhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other factors.

关键词： immune checkpoint     companion diagnosis     PD-L1     tumor mutation burden     immune score    

HTML PDF 收藏

High-throughput metabolomics reveals the perturbed metabolic pathways and biomarkers of Yang Huang syndrome

Heng Fang, Aihua Zhang, Xiaohang Zhou, Jingbo Yu, Qi Song, Xijun Wang

《医学前沿（英文）》 2020年 第14卷 第5期   页码 651-663 doi: 10.1007/s11684-019-0709-5

摘要： High-throughput metabolomics can clarify the underlying molecular mechanism of diseases via the qualitative and quantitative analysis of metabolites. This study used the established Yang Huang syndrome (YHS) mouse model to evaluate the efficacy of geniposide (GEN). Urine metabolic data were quantified by ultra-performance liquid chromatography–tandem mass spectrometry. The non-target screening of the massive biological information dataset was performed, and a total of 33 metabolites, including tyramine glucuronide, aurine, and L-cysteine, were identified relating to YHS. These differential metabolites directly participated in the disturbance of phase I reaction and hydrophilic transformation of bilirubin. Interestingly, they were completely reversed by GEN. While, as the auxiliary technical means, we also focused on the molecular prediction and docking results in network pharmacological and integrated analysis part. We used integrated analysis to communicate the multiple results of metabolomics and network pharmacology. This study is the first to report that GEN indirectly regulates the metabolite “tyramine glucuronide” through its direct effect on the target heme oxygenase 1 . Meanwhile, heme oxygenase-1, a prediction of network pharmacology, was the confirmed metabolic enzyme of phase I reaction in hepatocytes. Our study indicated that the combination of high-throughput metabolomics and network pharmacology is a robust combination for deciphering the pathogenesis of the traditional Chinese medicine (TCM) syndrome.

关键词： metabolomics     liquid chromatography-mass spectrometry     metabolites     metabolic pathways    

HTML PDF 收藏

早期监测肝细胞癌的新型非蛋白生物标志物 Review

Ghassan K. Abou-Alfa, 吴琳, Augusto Villanueva

《工程（英文）》 2021年 第7卷 第10期   页码 1369-1374 doi: 10.1016/j.eng.2021.02.020

摘要：

肝细胞癌（HCC）早期检测是对处于早期阶段的肝细胞癌进行检出的方法，对降低高风险患者的HCC死亡率至关重要。然而，对于早期HCC，目前仍然缺乏具有高度灵敏性和特异性的监测生物标志物。近年来，人们对循环系统中可检测到的肿瘤源性分子特征进行了大量研究，比如循环肿瘤脱氧核糖核酸（ctDNA）和循环肿瘤核糖核酸（ctRNA），以探讨它们作为多种肿瘤类型的候选非侵入性生物标志物的潜力。本文汇总了目前有关早期HCC检测的新方法及应用的研究。

关键词： 肝细胞癌     早期检测     生物标志物     液体活检    

HTML PDF 收藏

从药物开发的角度看工程化T细胞疗法 Review

Fang Chen, Joseph A. Fraietta, Carl H. June, 许中伟, J. Joseph Melenhorst, Simon F. Lacey

《工程（英文）》 2019年 第5卷 第1期   页码 140-149 doi: 10.1016/j.eng.2018.11.010

摘要：

癌症是全世界人口死亡的主要原因之一。细胞治疗的最新进展表明，其有可能为某些癌症患者带来第二次生命的机会。与化合物和蛋白质不同，细胞是活的、可自我复制的药物，具有精准的特异性。例如，经基因修饰后，T 细胞可表达嵌合抗原受体（chimeric antigen receptor，CAR），使其能够识别并杀死肿瘤细胞，并形成一个记忆库，准备回击持续存在的恶性细胞。抗CD19 嵌合抗原受体T 细胞（CAR T cells，CART19）对某些恶性肿瘤具有显著的临床疗效。CART19 的开发过程基本上遵循了“一个基因，一种药物，一种疾病”的传统模式，该模式源于Paul Ehrlich 提出的“魔法子弹”理念。随着制药行业的主要参与者联手使这种新型“活药物”商业化，以CART19 为例，与传统药物相比，研究其开发过程中的相似性和差异性非常有用。这样，我们可以将现有的知识融会贯通，找出推进类似策略最有效的方法。本文综述了基于生物标志物的分析方法在优化CAR结构、临床前研究和临床疗效评价、不良反应（AE）和CART19 细胞动力学方面的应用。同时还探讨了能够发现最佳靶标、新型CAR 结合结构域以及预测临床反应和不良反应的生物标志物的先进技术和计算工具。我们相信，就像胂凡纳明的发现开创了合成药物时代一样，CART19 的成功能够带来其他工程化T 细胞疗法的发展。

关键词： 工程化T细胞疗法     嵌合抗原受体     药物开发过程     生物标志物     CAR19     CART19    

HTML PDF 收藏

中医方证代谢组学——中药效应评价的有效途径 Review

张爱华, 孙晖, 闫广利, 韩莹, 赵琦琦, 王喜军

《工程（英文）》 2019年 第5卷 第1期   页码 60-68 doi: 10.1016/j.eng.2018.11.008

摘要：

有效性评价是发现中药药效物质基础、先导化合物和质量标志物的重要前提，因此急需建立一种生物学语言，将中药有效性科学地表达出来，进一步凸显中医药的实用价值。证候和方剂是中医药的重要组成部分，与中药有效性直接相关。我们以证候和方剂为研究对象，建立了科学评价中药有效性的创新方法学体系——中医方证代谢组学。它将中药血清药物化学理论与代谢组学技术有机整合，在解决证候生物标记物的基础上，建立方剂药效生物评价体系，发现并确认中药药效物质基础。该策略为提高中医理论和临床实践的科学价值提供了有力支持。本文概述了中医方证代谢组学的研究策略，利用该方法揭示临床常见中医证候生物标记物及开展相关方剂的有效性评价研究，着重阐述了中药药效物质基础及质量标记物的发现。

关键词： 中医方证代谢组学     中药血清药物化学     有效性     代谢组学     证候     生物标记物     质量标记物    

HTML PDF 收藏

Microbial responses to combined oxidation and catalysis treatment of 1,4-dioxane and co-contaminants in groundwater and soil

Yu Miao, Nicholas W. Johnson, Kimberly Heck, Sujin Guo, Camilah D. Powell, Thien Phan, Phillip B. Gedalanga, David T. Adamson, Charles J. Newell, Michael S. Wong, Shaily Mahendra

《环境科学与工程前沿（英文）》 2018年 第12卷 第5期 doi: 10.1007/s11783-018-1071-6

摘要：

Groundwater microbial community was altered after catalysis and chemical oxidation.

The coupled treatment train removed 90% 1,4-dioxane regardless of co-contaminants.

Dynamics of microbial populations varied along with different treatment stages.

Many microbial taxa exhibited resilience against oxidative and catalytic treatments.

Metagenomic analysis will be valuable for long-term management of polluted sites.

关键词： Coupled treatments     Chlorinated solvents     Diethylene ether     Biological diversity     Microbial populations     Biomarkers    

HTML PDF 收藏

标题 作者 时间 类型 操作

Sepsis biomarkers: an omics perspective

null

期刊论文

Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets

null

期刊论文

Progress on molecular biomarkers and classification of malignant gliomas

null

期刊论文

Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases

Zhen Xiang, Yingyan Yu

期刊论文

Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular

Weiqi Rong, Yang Zhang, Lei Yang, Lin Feng, Baojun Wei, Fan Wu, Liming Wang, Yanning Gao, Shujun Cheng, Jianxiong Wu, Ting Xiao

期刊论文

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

期刊论文

High-throughput metabolomics reveals the perturbed metabolic pathways and biomarkers of Yang Huang syndrome

Heng Fang, Aihua Zhang, Xiaohang Zhou, Jingbo Yu, Qi Song, Xijun Wang

期刊论文

早期监测肝细胞癌的新型非蛋白生物标志物

Ghassan K. Abou-Alfa, 吴琳, Augusto Villanueva

期刊论文

从药物开发的角度看工程化T细胞疗法

Fang Chen, Joseph A. Fraietta, Carl H. June, 许中伟, J. Joseph Melenhorst, Simon F. Lacey

期刊论文

中医方证代谢组学——中药效应评价的有效途径

张爱华, 孙晖, 闫广利, 韩莹, 赵琦琦, 王喜军

期刊论文

Microbial responses to combined oxidation and catalysis treatment of 1,4-dioxane and co-contaminants in groundwater and soil

Yu Miao, Nicholas W. Johnson, Kimberly Heck, Sujin Guo, Camilah D. Powell, Thien Phan, Phillip B. Gedalanga, David T. Adamson, Charles J. Newell, Michael S. Wong, Shaily Mahendra

期刊论文